Tocilizumab [375823-41-9]
Cat# HY-P9917-5mg
Size : 5mg
Brand : MedChemExpress
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
For research use only. We do not sell to patients.
Tocilizumab Chemical Structure
CAS No. : 375823-41-9
*
This product is a controlled substance and not for sale in your territory.
- •J Biomed Sci. 2022 Nov 24;29(1):101. [Abstract]
- •Cell Death Dis. 2021 Dec 20;13(1):16. [Abstract]
- •Breast Cancer Res. 2023 Apr 17;25(1):43. [Abstract]
- •Immunology. 2023 Apr 17.
- •Phytomedicine. 2023 Jan 11;111:154659. [Abstract]
- •Cell Biol Toxicol. 2021 Oct 25. [Abstract]
- •Sci Rep. 2023 Aug 14;13(1):13231. [Abstract]
- •Biochem Pharmacol. 2023 May 19;213:115618. [Abstract]
- •Carcinogenesis. 2023 Mar 20;bgad013. [Abstract]
- •Sci Rep. 2022 Jan 20;12(1):1075. [Abstract]
- •Endocr Relat Cancer. 2023 Jun 1;ERC-23-0130. [Abstract]
- •Oral Dis. 2023 May 30. [Abstract]
- •Int J Chron Obstruct Pulmon Dis. 2023 Apr 13.
- •Biochem Bioph Res Co. 2023 Feb 19.
- •Toxicol Appl Pharmacol. 2022 Feb 11;115921. [Abstract]
- •SSRN. 2024 Feb 7.
- •Research Square Print. October 3rd, 2022.
- •Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.
Biological Activity
Purity & Documentation
References
Customer Review
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease). | |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
In Vitro | Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab.? Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml.? Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells.? Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay
Cell Cytotoxicity Assay
Western Blot Analysis
RT-PCR
| ||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vivo | Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains.? Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|